• Molecular NameNedocromil
  • SynonymNA
  • Weight371.345
  • Drugbank_IDDB00716
  • ACS_NO69049-73-6
  • Show 2D model
  • LogP (experiment)2.22
  • LogP (predicted, AB/LogP v2.0)1.91
  • pkaN/A
  • LogD (pH=7, predicted)-3.09
  • Solubility (experiment)0.145 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.87
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.08
  • No.of HBond Donors2
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds5
  • TPSA121.21
  • StatusFDA approved
  • AdministrationInhalation and eye drops
  • PharmacologyA medication used to prevent wheezing, shortness of breath, and other breathing problems caused by asthma.
  • Absorption_value3.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability3.0
  • Protein binding89.0
  • Volume of distribution (VD)0.43 L/kg (after a 6 μg/kg, 30 min intravenous dose).
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNedocromil is not metabolized in man or animals.
  • Half life1.5~3.3 h
  • ExcretionExcreted unchanged
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include headache, nasal congestion, ocular burning, irritation and stinging, unpleasant taste, cough, difficulty breathing, noisy breathing, shortness of breath, tightness in chest, wheezing, conjunctivitis, blurred vision, change in color vision, difficulty seeing at night, increased sensitivity of eyes to sunlight.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A